We are live on
!
Find out more
CCM
Consonance Capital Management Portfolio holdings
AUM
$7.28M
1-Year Est. Return
43.59%
This Fund
S&P 500
This Quarter
Est. Return
+16.35%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$995M
AUM Growth
-$103M
(-9.4%)
Cap. Flow
-$165M
Cap. Flow
% of AUM
-16.56%
Top 10 Holdings %
Top 10 Hldgs %
79.85%
Holding
33
New
6
Increased
13
Reduced
8
Closed
5
Top Buys
| 1 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
+$29.1M |
| 2 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$25.9M |
| 3 |
Celldex Therapeutics
CLDX
|
+$19.9M |
| 4 |
Pacific Biosciences
PACB
|
+$19.6M |
| 5 |
CSII
Cardiovascular Systems, Inc.
CSII
|
+$9.17M |
Top Sells
| 1 |
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
|
+$87.3M |
| 2 |
United Therapeutics
UTHR
|
+$58.5M |
| 3 |
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
|
+$48M |
| 4 |
Supernus Pharmaceuticals
SUPN
|
+$43.1M |
| 5 |
PTX
Pernix Therapeutics Holdings, Inc.
PTX
|
+$34.9M |
Sector Composition
| 1 | Healthcare | 83.48% |
| 2 | Technology | 0.16% |
| 3 | Financials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Travere Therapeutics
TVTX
$5.28B
| $113M | 11.33% |
3,400,323
+292,613
| +9% | +$8.01M |
|
|
INSY
2
DELISTED
Insys Therapeutics, Inc.
INSY
| $107M | 10.77% |
2,984,094
+265,600
| +10% | +$8.27M |
|
|
EGRX
3
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $95.7M | 9.61% |
1,183,406
+447,484
| +61% | +$29.1M |
|
4
AbbVie
ABBV
$431B
| $87.3M | 8.77% |
1,298,900
+121,000
| +10% | +$7.9M |
|
|
AKRX
5
DELISTED
Akorn Inc
AKRX
| $80.5M | 8.09% |
1,843,756
-94,729
| -5% | -$4.38M |
|
|
6
United Therapeutics
UTHR
$22.6B
| $67.4M | 6.77% |
387,186
-325,000
| -46% | -$58.5M |
|
7
ANI Pharmaceuticals
ANIP
$1.84B
| $65.5M | 6.58% |
1,055,791
-68,876
| -6% | -$4.1M |
|
|
CSII
8
DELISTED
Cardiovascular Systems, Inc.
CSII
| $65.5M | 6.58% |
2,476,287
+283,787
| +13% | +$9.17M |
|
9
Orthofix Medical
OFIX
$456M
| $57.2M | 5.74% |
1,725,697
+145,479
| +9% | +$5M |
|
10
Enanta Pharmaceuticals
ENTA
$385M
| $55.8M | 5.61% |
1,241,321
-311,641
| -20% | -$12.1M |
|
|
11
Pacific Biosciences
PACB
$475M
| $31.1M | 3.12% |
5,398,861
+3,395,890
| +170% | +$19.6M |
|
|
CLVS
12
DELISTED
Clovis Oncology, Inc.
CLVS
| $26.6M | 2.68% |
+303,131
| New | +$25.9M |
|
|
OSIR
13
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
| $22.9M | 2.3% |
1,176,195
-22,141
| -2% | -$392K |
|
14
Catalyst Pharmaceutical
CPRX
$3.85B
| $22.8M | 2.29% |
5,517,885
+668,015
| +14% | +$2.66M |
|
|
15
Celldex Therapeutics
CLDX
$3.01B
| $19M | 1.9% |
+50,117
| New | +$19.9M |
|
|
EPRS
16
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $12.9M | 1.3% |
2,265,988
+742,215
| +49% | +$5.07M |
|
|
DSCI
17
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $12.6M | 1.27% |
1,760,649
+128,022
| +8% | +$963K |
|
|
TVTY
18
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $12.1M | 1.22% |
1,010,025
-706,282
| -41% | -$11.7M |
|
19
ADMA Biologics
ADMA
$2.01B
| $9.58M | 0.96% |
1,034,721
+48,214
| +5% | +$417K |
|
20
Vericel Corp
VCEL
$2.39B
| $8.4M | 0.84% |
2,352,940
| – | – |
|
|
NSTG
21
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.93M | 0.7% |
+449,325
| New | +$6M |
|
|
MSLI
22
DELISTED
Merus Labs International Inc.
MSLI
| $3.83M | 0.38% |
1,641,588
+272,974
| +20% | +$662K |
|
|
SIEN
23
DELISTED
Sientra, Inc.
SIEN
| $3.33M | 0.34% |
+13,214
| New | +$2.7M |
|
24
Veracyte
VCYT
$4.75B
| $3.33M | 0.33% |
298,966
+63,106
| +27% | +$621K |
|
25
Lineage Cell Therapeutics
LCTX
$304M
| $2.38M | 0.24% |
812,222
-1,173,357
| -59% | -$4.55M |
|
Similar funds
GPC
BPM
TVPI
DCI
TPMI
TP
SCG
CVGI